Selected research
Industry Research
CINV Existing and Pipeline Drugs Industry Research Report 2026
Market perspective
The global CINV Existing and Pipeline Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for CINV Existing and Pipeline Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for CINV Existing and Pipeline Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for CINV Existing and Pipeline Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of CINV Existing and Pipeline Drugs include Merck, GlaxoSmithKline, Tesaro, Heron Therapeutics and Helsinn, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global CINV Existing and Pipeline Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (Kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Kg) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
CINV Existing and Pipeline Drugs Market by Company
Merck
GlaxoSmithKline
Tesaro
Heron Therapeutics
Helsinn
CINV Existing and Pipeline Drugs Segment by Type
Akynzeo
Aloxi
Emend
Kytril Generic
Rolapitant
SUSTOL
Zofran Generic
CINV Existing and Pipeline Drugs Segment by Application
Specialty Clinics
Diagnostic Centers Therapeutics
Hospital Pharmacies
Hospitals
Drugstores
CINV Existing and Pipeline Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CINV Existing and Pipeline Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CINV Existing and Pipeline Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CINV Existing and Pipeline Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of CINV Existing and Pipeline Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of CINV Existing and Pipeline Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of CINV Existing and Pipeline Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Akynzeo
- Aloxi
- Emend
- Kytril Generic
- Rolapitant
- SUSTOL
- Zofran Generic
Applications
- Specialty Clinics
- Diagnostic Centers Therapeutics
- Hospital Pharmacies
- Hospitals
- Drugstores
Companies covered
- Merck
- GlaxoSmithKline
- Tesaro
- Heron Therapeutics
- Helsinn
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global CINV Existing and Pipeline Drugs Market Size (2021-2032)
- 2.2.2 Global CINV Existing and Pipeline Drugs Sales (2021-2032)
- 2.2.3 Global CINV Existing and Pipeline Drugs Market Average Price (2021-2032)
- 2.3 CINV Existing and Pipeline Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Akynzeo
- 2.3.3 Aloxi
- 2.3.4 Emend
- 2.3.5 Kytril Generic
- 2.3.6 Rolapitant
- 2.3.7 SUSTOL
- 2.3.8 Zofran Generic
- 2.4 CINV Existing and Pipeline Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Specialty Clinics
- 2.4.3 Diagnostic Centers Therapeutics
- 2.4.4 Hospital Pharmacies
- 2.4.5 Hospitals
- 2.4.6 Drugstores
3 Market Competitive Landscape by Manufacturers
- 3.1 Global CINV Existing and Pipeline Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global CINV Existing and Pipeline Drugs Sales (Kg) of Manufacturers (2021-2026)
- 3.3 Global CINV Existing and Pipeline Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global CINV Existing and Pipeline Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global CINV Existing and Pipeline Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of CINV Existing and Pipeline Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of CINV Existing and Pipeline Drugs, Product Type & Application
- 3.8 Global Manufacturers of CINV Existing and Pipeline Drugs, Established Date
- 3.9 Global CINV Existing and Pipeline Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Merck
- 4.1.1 Merck Company Information
- 4.1.2 Merck Business Overview
- 4.1.3 Merck CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Merck CINV Existing and Pipeline Drugs Product Portfolio
- 4.1.5 Merck Recent Developments
- 4.2 GlaxoSmithKline
- 4.2.1 GlaxoSmithKline Company Information
- 4.2.2 GlaxoSmithKline Business Overview
- 4.2.3 GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 GlaxoSmithKline CINV Existing and Pipeline Drugs Product Portfolio
- 4.2.5 GlaxoSmithKline Recent Developments
- 4.3 Tesaro
- 4.3.1 Tesaro Company Information
- 4.3.2 Tesaro Business Overview
- 4.3.3 Tesaro CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Tesaro CINV Existing and Pipeline Drugs Product Portfolio
- 4.3.5 Tesaro Recent Developments
- 4.4 Heron Therapeutics
- 4.4.1 Heron Therapeutics Company Information
- 4.4.2 Heron Therapeutics Business Overview
- 4.4.3 Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Heron Therapeutics CINV Existing and Pipeline Drugs Product Portfolio
- 4.4.5 Heron Therapeutics Recent Developments
- 4.5 Helsinn
- 4.5.1 Helsinn Company Information
- 4.5.2 Helsinn Business Overview
- 4.5.3 Helsinn CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Helsinn CINV Existing and Pipeline Drugs Product Portfolio
- 4.5.5 Helsinn Recent Developments
5 Global CINV Existing and Pipeline Drugs Market Scenario by Region
- 5.1 Global CINV Existing and Pipeline Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global CINV Existing and Pipeline Drugs Sales by Region: 2021-2032
- 5.2.1 Global CINV Existing and Pipeline Drugs Sales by Region: 2021-2026
- 5.2.2 Global CINV Existing and Pipeline Drugs Sales by Region: 2027-2032
- 5.3 Global CINV Existing and Pipeline Drugs Revenue by Region: 2021-2032
- 5.3.1 Global CINV Existing and Pipeline Drugs Revenue by Region: 2021-2026
- 5.3.2 Global CINV Existing and Pipeline Drugs Revenue by Region: 2027-2032
- 5.4 North America CINV Existing and Pipeline Drugs Market Facts & Figures by Country
- 5.4.1 North America CINV Existing and Pipeline Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America CINV Existing and Pipeline Drugs Sales by Country (2021-2032)
- 5.4.3 North America CINV Existing and Pipeline Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe CINV Existing and Pipeline Drugs Market Facts & Figures by Country
- 5.5.1 Europe CINV Existing and Pipeline Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe CINV Existing and Pipeline Drugs Sales by Country (2021-2032)
- 5.5.3 Europe CINV Existing and Pipeline Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific CINV Existing and Pipeline Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific CINV Existing and Pipeline Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific CINV Existing and Pipeline Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific CINV Existing and Pipeline Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America CINV Existing and Pipeline Drugs Market Facts & Figures by Country
- 5.7.1 South America CINV Existing and Pipeline Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America CINV Existing and Pipeline Drugs Sales by Country (2021-2032)
- 5.7.3 South America CINV Existing and Pipeline Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa CINV Existing and Pipeline Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa CINV Existing and Pipeline Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa CINV Existing and Pipeline Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa CINV Existing and Pipeline Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global CINV Existing and Pipeline Drugs Sales by Type (2021-2032)
- 6.1.1 Global CINV Existing and Pipeline Drugs Sales by Type (2021-2032) & (Kg)
- 6.1.2 Global CINV Existing and Pipeline Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global CINV Existing and Pipeline Drugs Revenue by Type (2021-2032)
- 6.2.1 Global CINV Existing and Pipeline Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global CINV Existing and Pipeline Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global CINV Existing and Pipeline Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global CINV Existing and Pipeline Drugs Sales by Application (2021-2032)
- 7.1.1 Global CINV Existing and Pipeline Drugs Sales by Application (2021-2032) & (Kg)
- 7.1.2 Global CINV Existing and Pipeline Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global CINV Existing and Pipeline Drugs Revenue by Application (2021-2032)
- 7.2.1 Global CINV Existing and Pipeline Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global CINV Existing and Pipeline Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global CINV Existing and Pipeline Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 CINV Existing and Pipeline Drugs Value Chain Analysis
- 8.1.1 CINV Existing and Pipeline Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 CINV Existing and Pipeline Drugs Production Mode & Process
- 8.2 CINV Existing and Pipeline Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 CINV Existing and Pipeline Drugs Distributors
- 8.2.3 CINV Existing and Pipeline Drugs Customers
9 Global CINV Existing and Pipeline Drugs Analyzing Market Dynamics
- 9.1 CINV Existing and Pipeline Drugs Industry Trends
- 9.2 CINV Existing and Pipeline Drugs Industry Drivers
- 9.3 CINV Existing and Pipeline Drugs Industry Opportunities and Challenges
- 9.4 CINV Existing and Pipeline Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst